Why the study?
Chronic inflammation plays an important role in coronary microvascular dysfunction, but whether omega-3 fatty acid treatment attenuates this dysfunction remains unknown.
Does omega-3 fatty acid treatment attenuate coronary microvascular dysfunction?
Does omega-3 fatty acid treatment attenuate coronary microvascular dysfunction?
This review highlights the theoretical potential of omega-3 fatty acids to attenuate coronary microvascular dysfunction by modulating chronic inflammation, though direct clinical evidence remains lacking.
Answers are grounded in this paper and cite their sources.
Should not change CMD practice; leaves open need for RCTs testing anti-inflammatory effects.
Coronary microvascular dysfunction is a ubiquitous pathologic process that is operational in ischemia with no obstructive coronary artery disease and other cardiovascular disorders including heart failure with preserved ejection fraction. It may, in fact, be a manifestation of a multi-systemic condition of small vessel dysfunction that also affects the brain and kidneys. While the pathophysiology driving coronary microvascular dysfunction is multifactorial, chronic inflammation plays an important role. Resolution of inflammation is an active process mediated, in part, by a family of locally active mediators biosynthesized from omega-3 fatty acids, collectively referred to as specialized pro-resolving mediators. Omega-3 fatty acid treatment modulates inflammation and is associated with improved cardiovascular outcomes and attenuation of plaque progression on cardiovascular imaging. Whether omega-3 fatty acid treatment attenuates coronary microvascular dysfunction is unknown.
No takes yet. Share an insight, caveat, or question.
Keeley et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: